147.10 USD
+0.17
0.12%
At close Updated Sep 18, 4:00 PM EDT
Pre-market
After hours
147.10
0.00
0%
1 day
0.12%
5 days
-1.7%
1 month
-3.43%
3 months
-5.13%
6 months
-10.54%
Year to date
-9.54%
1 year
-25.13%
5 years
-8.56%
10 years
226.02%
 

About: Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Employees: 13,800

0
Funds holding %
of 7,463 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

7% more funds holding in top 10

Funds holding in top 10: 14 [Q1] → 15 (+1) [Q2]

2.42% more ownership

Funds ownership: 92.44% [Q1] → 94.86% (+2.42%) [Q2]

8% more first-time investments, than exits

New positions opened: 149 | Existing positions closed: 138

5% more call options, than puts

Call options by funds: $248M | Put options by funds: $236M

0% more repeat investments, than reductions

Existing positions increased: 725 | Existing positions reduced: 725

4% less capital invested

Capital invested by funds: $68.1B [Q1] → $65.7B (-$2.39B) [Q2]

1% less funds holding

Funds holding: 1,866 [Q1] → 1,843 (-23) [Q2]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$155
5% upside
Avg. target
$180
22% upside
High target
$215
46% upside

4 analyst ratings

positive
50%
neutral
50%
negative
0%
Argus Research
Jasper Hellweg
$190
Buy
Reiterated
9 Sep 2025
Piper Sandler
David Westenberg
$215
Overweight
Maintained
11 Aug 2025
Leerink Partners
Daniel Clark
$155
Market Perform
Downgraded
17 Jul 2025
Stifel
Jonathan Block
$160
Hold
Downgraded
18 Jun 2025

Financial journalist opinion

Based on 10 articles about ZTS published over the past 30 days

Neutral
Zacks Investment Research
2 days ago
Zoetis (ZTS) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Zoetis (ZTS) stood at $146.25, denoting a -1.32% move from the preceding trading day.
Zoetis (ZTS) Stock Declines While Market Improves: Some Information for Investors
Positive
Zacks Investment Research
3 days ago
Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain
ZTS secures CVMP's positive opinion recommending the approval of Portela, a long-acting OA pain therapy for cats, with final decision expected in late 2025.
Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain
Neutral
Zacks Investment Research
6 days ago
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Drugs sector might want to consider either Sandoz Group AG Sponsored ADR (SDZNY) or Zoetis (ZTS). But which of these two stocks is more attractive to value investors?
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Neutral
Business Wire
6 days ago
Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--If approved, Zoetis' Portela will be the first long-acting anti-NGF mAb therapy for cats and is designed to provide 3 months of OA pain relief.
Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats
Negative
Zacks Investment Research
8 days ago
Zoetis (ZTS) Stock Sinks As Market Gains: Here's Why
Zoetis (ZTS) reached $149.79 at the closing of the latest trading day, reflecting a -1.29% change compared to its last close.
Zoetis (ZTS) Stock Sinks As Market Gains: Here's Why
Neutral
Seeking Alpha
10 days ago
Zoetis Inc. (ZTS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Zoetis Inc. (NYSE:ZTS ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 1:05 PM EDT Company Participants Kristin Peck - CEO & Director Wetteny Joseph - Executive VP & CFO Conference Call Participants Erin Wilson Wright - Morgan Stanley, Research Division Presentation Erin Wilson Wright Equity Analyst Good afternoon, everyone. Welcome to the Morgan Stanley Healthcare Conference.
Zoetis Inc. (ZTS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Positive
Seeking Alpha
17 days ago
Zoetis: A Solid Dividend Growth Investment For The Long Haul
Zoetis is a global leader in animal health with strong organic growth, robust product innovation, and strategic M&A driving long-term revenue and earnings expansion. The company boasts exceptional dividend safety, a 13-year double-digit dividend growth streak, and a conservative payout ratio, making it ideal for dividend growth investors. Zoetis's current valuation is slightly below historical averages, presenting an attractive entry point with the stock trading near fair value and strong analyst support.
Zoetis: A Solid Dividend Growth Investment For The Long Haul
Positive
Zacks Investment Research
22 days ago
SDZNY or ZTS: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Drugs sector might want to consider either Sandoz Group AG Sponsored ADR (SDZNY) or Zoetis (ZTS). But which of these two companies is the best option for those looking for undervalued stocks?
SDZNY or ZTS: Which Is the Better Value Stock Right Now?
Neutral
Business Wire
22 days ago
Zoetis to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8 at 1:05 p.m. ET. Investors and other interested parties can access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event. About Zoetis As the world's.
Zoetis to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Positive
Seeking Alpha
24 days ago
Zoetis: Why I Decided To Invest In The Stock
Zoetis remains the global leader in animal health, with 68% of revenue from companion animals. Q2 results showed 8% organic sales growth and 15% adjusted earnings growth. Librela sales in the U.S. declined 16% due to reported side effect concerns.
Zoetis: Why I Decided To Invest In The Stock
Charts implemented using Lightweight Charts™